Astral demerger 2026: 1:1 Astral Chemie spin-off details

What Astral announced and why it matters

Astral Ltd. has approved a corporate restructuring that will split its Chemicals business into a separate company, Astral Chemie Limited, while keeping the Plumbing business within the existing listed entity. The plan was disclosed through an exchange filing, and it triggered a sharp reaction in the stock during the following trading session.

The demerger is being positioned as a value-unlocking move that could allow investors to value the businesses independently. Market participants and brokerages, however, have also highlighted that the restructuring changes the growth narrative and makes execution and segment-level performance more important for valuation.

Board approval: composite scheme and the group structure

Astral said its Board approved a Composite Scheme of Arrangement that includes two linked steps. First, the Chemicals business will be demerged into Astral Chemie Limited on a going-concern basis, along with related assets and liabilities. Second, Al-Aziz Plastics Private Limited will be amalgamated with Astral Ltd.

The company said the scheme is designed to simplify the corporate structure and create two focused platforms. In the disclosed structure, Astral continues as the plumbing-focused listed company, while Astral Chemie becomes the chemicals-focused platform.

Management has indicated that, with a major capital spending cycle nearing its end, a split can help each unit focus capital allocation and operational priorities more efficiently.

Shareholder entitlement: 1:1 share issuance in Astral Chemie

Under the scheme, eligible shareholders of Astral Ltd. will receive one equity share of Astral Chemie Limited for every one equity share held in Astral. The company specified that the face value is Re 1 each for both the Astral share and the Astral Chemie share under the entitlement.

The information provided also states there will be no cash consideration under the scheme. It was further noted that there will be no change in the shareholding pattern of the demerged company, as Astral Chemie’s shareholding pattern is expected to mirror Astral’s.

Regulatory path and expected timeline (9-12 months)

The scheme is subject to multiple approvals before it becomes effective. The approvals listed include the National Company Law Tribunal (NCLT), SEBI, stock exchanges, shareholders, creditors, and other regulators as applicable.

The process timeline cited by management and market commentary is nine to twelve months. Equirus Securities said the demerger is expected to become effective after 9-12 months and should eliminate any conglomerate discount by enabling independent valuation of the resulting businesses.

Astral has also indicated that Astral Chemie’s equity shares are proposed to be listed on the NSE and BSE, subject to receiving the required approvals.

What sits in the Chemicals business

The materials provided describe the chemicals undertaking as including products such as adhesives, sealants, paints, coatings, construction chemicals, and specialty chemicals. Astral has said the undertaking will move to Astral Chemie on a going-concern basis, along with its assets and liabilities.

This definition matters for investors because it clarifies what revenue and profit streams shift to the new entity and what remains within Astral after the demerger.

Financial snapshot: Chemicals revenue share in FY26

Astral disclosed that for the year ended March 31, 2026 (FY26), the Chemicals business reported turnover of ₹1,266.3 crore, which was stated to be 21% of Astral’s total turnover.

This disclosure provides an initial scale indicator for Astral Chemie relative to the rest of the group, and it frames the size of the earnings base that will eventually be valued separately once the scheme is implemented and the resulting company is listed.

Stock market reaction: Astral shares fall after the update

Astral shares declined sharply after investors reacted to the demerger update. During the trading session on Monday, June 29, the stock fell 6.5% to an early market low of ₹1,390, compared with the previous close of ₹1,486.90, according to NSE data cited in the text.

Another market snapshot in the provided material showed Astral at ₹1,486.90, down 3.24%, and also referenced a change of -₹49.80. A separate line stated a current price of ₹1,498.30. Taken together, the data points show the stock was volatile around the announcement and subsequent trading.

Brokerage view: Motilal Oswal cuts target price to ₹1,710

Motilal Oswal lowered its target price for Astral Ltd. to ₹1,710 per share. The brokerage linked part of the reset to the stock’s roughly 15% decline from March highs.

Motilal Oswal maintained a positive view on the company, but it also noted that future valuation will depend on the growth of the new paint division and the execution of the restructuring. The brokerage also referenced that the stock was trading at around 45 times its estimated earnings for fiscal year 2028.

Growth concerns flagged for the remaining business

While the stated intent of the demerger is sharper focus, capital allocation, and improved margins, experts also flagged a risk: the demerger could potentially impact growth prospects of the remaining, relatively sub-scale Paints & Adhesives segment.

This point matters because, once the chemicals undertaking is carved out, investors will likely examine the remaining mix and growth drivers more closely, rather than valuing Astral as a combined platform.

Key facts table

Market impact and why the structure can change valuation

The immediate market impact was visible in the stock’s intraday decline after the exchange filing update. Beyond the price move, the scheme introduces multiple valuation “checkpoints” for investors: regulatory approvals, scheme effectiveness, and the eventual listing of Astral Chemie.

If the demerger proceeds as planned, the market will have separate price discovery for Astral’s remaining listed business and for Astral Chemie. Equirus Securities explicitly linked the move to removing a conglomerate discount, which is another way of saying investors can assign different multiples to plumbing-focused operations and to the chemicals platform.

Conclusion: what investors will track next

Astral’s board-approved composite scheme sets up a Chemicals demerger into Astral Chemie with a 1:1 share entitlement and proposes a separate listing on NSE and BSE, alongside the amalgamation of Al-Aziz Plastics into Astral.

Next milestones are approvals from SEBI, stock exchanges, NCLT, shareholders, and creditors, with the company indicating a 9-12 month window for completion. Until then, investors are likely to track clarity on segment growth, particularly around the paints-related plans referenced by brokerages, and execution progress on the restructuring steps already disclosed.